Arrowhead Pharmaceuticals (ARWR)

Quick facts

Marketed products

• Redemplo · Metabolic
  Plozasiran reduces hepatic and serum apoC-III protein by degrading apoC-III mRNA via RNA interference, leading to increased clearance of serum triglycerides.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Arrowhead Pharmaceuticals portfolio CI brief
• Arrowhead Pharmaceuticals pipeline updates RSS